Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers

Journal of Clinical Pharmacology

Volumn 48, Issue 12, 2008, Pages 1400-1410

  Frey, Reiner ^a   Mück, Wolfgang ^a   Unger, Sigrun ^a   Artmeier Brandt, Ulrike ^a   Weimann, Gerrit ^a   Wensing, Georg ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Cyclic GMP; Drug therapy; Heart failure; Phase I clinical trial; Soluble guanylate cyclase

Indexed keywords

4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; ALDOSTERONE; ANGIOTENSIN II; CYCLIC GMP; GUANYLATE CYCLASE ACTIVATOR; NORADRENALIN; PLACEBO; RENIN;

ABDOMINAL DISTENSION; ADULT; AGE DISTRIBUTION; ALDOSTERONE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ETHNICITY; FLUSHING; HEADACHE; HEART AFTERLOAD; HEART FAILURE; HEART OUTPUT; HEART PRELOAD; HEART RATE; HEART STROKE VOLUME; HEARTBURN; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; INDIVIDUALIZATION; INTERINDIVIDUAL VARIABILITY; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; NAUSEA; NORMAL HUMAN; NOSE CONGESTION; PALLOR; PHARMACODYNAMICS; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SKIN IRRITATION; SKIN TINGLING; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VASODILATATION; VOLUNTEER;

ADULT; ANGIOTENSIN II; AREA UNDER CURVE; BENZOIC ACIDS; BLOOD PRESSURE; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATORS; GUANYLATE CYCLASE; HALF-LIFE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; NOREPINEPHRINE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RENIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57449087642     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008322906     Document Type: Article

References (12)

1. Allen LA, O'Connor CM Management of acute decompensated heart failure. CMAJ. 2007 ; 176: 797-805.
2. Nieminen MS, Bohm M., Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005 ; 26: 384-416.
3. McBride BF, White CM Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management. Pharmacotherapy. 2003 ; 23: 997-1020.
4. Munzel T., Genth-Zotz S., Hink U. Targeting heme-oxidized soluble guanylate cyclase. Solution for all cardiorenal problems in heart failure? Hypertension. 2007 ; 49: 974-976.
5. Evgenov OV, Pacher P., Schmidt PM, Hasko G., Schmidt HH, Stasch JP NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006 ; 5: 755-768.
6. Boerrigter G., Costello-Boerrigter LC, Cataliotti A., Lapp H., Stasch JP, Burnett JC Jr. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension. 2007 ; 49: 1128-1133.
7. WHO. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information. Geneva, Switzerland: World Health Organization. 2007 ;21: 133-190.
8. Stasch JP, Schmidt PM, Nedvetsky PI, et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest. 2006 ; 116: 2552-2561.
9. Hahn MG, Alonso-Alija C., Stoll F., et al. Design and synthesis of the first NO- and haem-independent sGC activator BAY 58-2667 for the treatment of acute decompensated heart failure. BMC Pharmacology. 2007 ; 7: P25.
10. Stasch JP, Schmidt P., Alonso-Alija C., et al. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol. 2002 ; 136: 773-783.
11. Hoffmann M., Thuss U. Cardiovascular effects of the soluble guanylate cyclase activator BAY 58-2667 in anaesthetized dogs. In: Hofmann F, Schmidt H, Stasch JP, eds. 3rd International Conference on cGMP Generators, Effectors, and Therapeutic Implications. Dresden, Germany: BMC Pharmacology; 2007.
12. Thadani U., Ripley TL Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina, and acute myocardial infarction. Expert Opin Drug Saf. 2007 ; 6: 385-396.